Key result
Q050A pay-for-performance incentive is linked to minimal increases in guideline-directed heart failure prescribing.
Why the study?
The Ministry of Health in Ontario implemented the Q050 billing code as a pay-for-performance incentive to support family physicians in managing heart failure, but its association with changes in HF medication prescriptions was unclear.
Does a pay-for-performance incentive billing code improve the prescription of guideline-directed heart failure medications in primary care patients with heart failure?
Cohort (n=39,425)
Does a pay-for-performance incentive billing code improve the prescription of guideline-directed heart failure medications in primary care patients with heart failure?
A pay-for-performance incentive for primary care physicians led to only a minimal increase in the prescription of disease-modifying heart failure medications, highlighting ongoing clinical inertia.
Answers are grounded in this paper and cite their sources.
Minimal prescribing gains after pay-for-performance incentive; leaves open whether alternative strategies can better overcome inertia in primary care HF management.
Background To support family physicians (FPs) in managing patients with heart failure (HF), the Ministry of Health in Ontario, Canada, implemented the Q050 billing code in 2008, a pay-for-performance (P4P) incentive for guideline-based HF care. We studied whether the incentive was associated with any change in the prescriptions of HF medications. Methods We identified all patients with HF in Ontario of age≥66, who were managed by FPs claiming the Q050 incentive between 2008 and 2021. We determined the proportion of patients who were prescribed renin-angiotensin system inhibitors (RASi), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and diuretics three months before and after the Q050 billing code was claimed for these patients. Where applicable, we classified the agents by whether they are guideline-directed as recommended by the Canadian Cardiovascular Society (CCS). Results We included 39,425 HF patients in the study. The median age was 80 (IQR 73-85) years; 49% were female. Compared to pre-Q050, there was an increase in RASi prescriptions from 45.2% to 45.8%, BB from 51.9% to 54.4%, MRA from 9.2% to 11.7%, and diuretics from 63.2% to 65.7% after the incentive (p<0.05). There was a decrease in those not on any HF medications from 27.5% to 24.9% (p<0.001). Those with newly diagnosed HF and prompt follow-up with FPs experienced the largest but clinically modest increase in HF medications. Conclusions The Q050 incentive led to a minimal increase in the prescription of HF medications; there is underutilization of disease-modifying agents.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) conducted a cohort in Heart failure (n=39,425). Q050A incentive billing code vs. 3 months prior to billing code claim was evaluated on Prescription of beta-blockers (p=<0.001). The Q050A pay-for-performance incentive billing code was associated with minimal increases in the prescription of heart failure medications, including an increase in beta-blocker use from 51.9% to 54.4%.
Synapse has enriched 10 related papers. Consider them for comparative context: